1982 BS (Chemistry, Botany & Zoology) Banares Hindu University
1985 MS (Biochemistry) Banares Hindu University
1989 PhD (Biochemistry) Banares Hindu University
To create an excellent research environment and mentoring to all laboratory members as well as to students who want to gain research experience. Our mission is to prepare our students to achieve their goals and become successful in the field of biomedical sciences.
My present research interest lies in studying cell signaling mechanisms of asbestos fibers-induced lung diseases including lung cancer and mesothelioma. We are exploring asbestos-induced signaling mechanisms in human mesothelial cells as well as in different mesothelioma cell lines to be targeted by different anti-cancer drugs in combination with pathway inhibitors. We are trying to elucidate possible mechanisms of asbestos-induced carcinogenesis. Mechanistically, we are focusing our investigations on how ERK cell signaling pathway plays a role in the development of malignant mesothelioma (MM). So far we have shown that ERK1, 2 and 5 and CREB are very important in mesothelioma pathogenesis. As a follow up we are running a preclinical trial with the ERK5 specific inhibitor, XMD8-92.
The current focus of our group is to demonstrate the role of inflammation with special emphasis on inflammasomes in MM pathogenesis. Our goal is to reveal the role of inflammasomes in development of asbestos–induced mesothelioma and to manipulate them to develop potential therapeutic strategies for MM.
We are also in the process of assessing differential susceptibility of pleural and peritoneal mesothelial cells to asbestos by Next Gen Sequencing (Massive Parallel Sequencing). This will help us understand why pleural mesothelioma is more common than peritoneal mesothelioma.
In addition, role(s) of exosomes in development and therapy of MM is also being explored. The goal of this project is to show if exosomes are the carriers of information to mesothelial cells for development of MM. We also hope to identify exosome signature as biomarkers of asbestos exposure for the early diagnosis of MM.
2011 - Present Research Associate Professor, Department of Pathology, University of Vermont, Burlington, VT
2001 - 2011 Research Assistant Professor, Department of Pathology, University of Vermont, Burlington, VT.
1997 - 1999 Visiting Scientist, University of Vermont, Vermont, USA
1991 - 1997 Central Drug Research Institute, Lucknow, India
1988 - 1990 USA Post-doctoral Research Associate, University of Michigan, Ann Arbor, Michigan
1985 - 1988 Junior and Senior Research Fellow in the Department of Pediatrics Institute of Medical Sciences, Banares Hindu University, Varanasi, India
2000 Best poster award in International Conference on Environmental and Occupational Lung Disease, hosted by Industrial Toxicology Research Centre, 29 October-2 November 2000 in Lucknow, India
2004 Best poster award from Vermont Cancer Center
2005 Travel award from GeneSifter
2008 Pilot award from Vermont Cancer Center/Lake Champlain Cancer Research Organization
2010 Invited panel reviewer for Peer Reviewed Medical Research Program (PRMRP)-DOD, FY10 for proposal review for IIRA and Technology/Therapeutic Development (TTD) categories. Mesothelioma Panel.
2011 Editorial Board Member of American Journal of Respiratory Cell and Molecular Biology (an American Thoracic Society Journal)
2014 Lathrop MJ, Sage EK, Macura SL, Brooks EM, Bonenfant NR, Sokocevic D, MacPherson MB, Beuschel SL, Dunaway CW, Shukla A, Janes SM, Steele C, Mossman BT, Weiss DJ. Mesenchymal Stromal Cells Expressing TRAIL Inhibit Tumor Growth and Alter the Tumor Microenvironment of Human Malignant Mesotheliomas in a Mouse Xenograft Model. Cancer Gene Therapy, 2014 (in press).
Role: Designed experiments, interpreted data, contributed stable cell lines and intellectual input.
2014 *Catherine Westbom, Anurag Shukla, Maximilian Macpherson, Elizabeth C. Yasewicz, Jill M. Miller, Stacie L. Beuschel, Chad Steel, Harvey I. Pass, Pamela M. Vacek and Arti Shukla. CREB-induced inflammation is important for malignant mesothelioma growth. American Journal of Pathology, 184, 2816-27, 2014.
Designed and performed experiments, analyzed data, wrote the manuscript and corresponding author.
This article was showcased on The American Journal of Pathology’s Facebook page (https://www.facebook.com/AJPathology) and on Twitter @AJPathology.
2014 *Thompson K Joyce, Westbom M Catherine, MacPherson B Maximilian, Mossman T Brooke, Heintz H Nicholas, Spiess Page, Shukla Arti. Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Particle and Fibre Toxicology 11(1):24. doi: 10.1186/1743-8977-11-24, 2014. PMCID:PMC4055279
Impact factor(2013): 9.18.
2014 Sayan Mutlay, Shukla Arti, MacPherson Maximilian, Macura Sherrill, Hillegass Jedd, Perkins Timothy, Thompson Joyce, Beuschel Stacie, and Mossman Brooke. ERK5 and CREB are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas. Am J Resp Cell Mol Biol. 2014, (in press).
Impact factor (2012): 5.125
For a complete list of Atri Shukla's publications, please visit PubMed.